Commitments And Contingencies (Narrative) (Details) (USD $)	1 Months Ended				3 Months Ended		9 Months Ended
	May 31, 2017	May 31, 2010	Nov. 30, 2008	May 31, 2007	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011 years sqft	Sep. 30, 2010	Dec. 31, 2010
Commitments And Contingencies [Line Items]
Number of clinical trials			3
Office space under lease, square feet							53,000
Average annual rental expense							$ 1,900,000
Rental agreement expiration date							March 2013
Number of lease renewal options							2
Number of years lease agreement, renewal option							5
Security deposit					1,300,000		1,300,000
Cash deposit					1,280,000		1,280,000		1,284,000
Rent expense from continuing operations					500,000	500,000	1,500,000	1,400,000
Number of senior officers with employment agreements							8
Annual employee benefits compensation committed							3,100,000
Severance agreements, aggregate amount							1,400,000
Severance agreement costs, next twelve months							1,300,000
Severance agreement costs, next two years							100,000
Annual product world wide manufacturing requirement percentage							100.00%
Advance notice period for termination of purchase contract, period							3
Initial advance notice period ending, date	May 2017						December 2018
Termination of agreement after any written notice, period					30		30
Additional increase in term on renewal of purchase contract, period	10
Advance notice period for termination of contract prior expiration of term, period							45
Additional period of continuous supply to be made by supplier on breach of contract, period							1
Tax contingencies		1,700,000		1,200,000
Increase in tax contingencies due to additional interest and penalties		500,000
Consideration payment per consulting agreement							20,000
Minimum [Member]
Commitments And Contingencies [Line Items]
Possible project payment percentage exceeding repayment obligation							120.00%
Minimum [Member] | Mountain View Pharmaceuticals And Duke University [Member]
Commitments And Contingencies [Line Items]
Percentage of royalty rate payable on net sales					8.00%		8.00%
Maximum [Member]
Commitments And Contingencies [Line Items]
Possible project payment percentage exceeding repayment obligation							300.00%
Maximum [Member] | Mountain View Pharmaceuticals And Duke University [Member]
Commitments And Contingencies [Line Items]
Percentage of royalty rate payable on net sales					12.00%		12.00%
Bio-Technology General (Israel) Ltd, [Member]
Commitments And Contingencies [Line Items]
Minimum percentage of purchase committed							80.00%
Expected future purchases, 12 months outlook					4,100,000		4,100,000
Non-refundable fees paid for potential future purchases							2,200,000
Fujifilm Diosynth Biotechnologies USA LLC [Member]
Commitments And Contingencies [Line Items]
Non-refundable fees paid for potential future purchases							1,000,000
Additional cost for re-execution of campaign					10,000,000		10,000,000
NOF Corporation [Member]
Commitments And Contingencies [Line Items]
Expected future purchases, 12 months outlook					2,800,000		2,800,000
Minimum percentage of supply to be made by supplier							75.00%
Percentage of minimum purchase obligation payable on termination					50.00%		50.00%
Percentage of minimum purchase obligation payable on breach of purchase contract					50.00%		50.00%
Sigma-Tau PharmaSource, Inc [Member]
Commitments And Contingencies [Line Items]
Expected future purchases, 12 months outlook					1,100,000		1,100,000
Mountain View Pharmaceuticals And Duke University [Member]
Commitments And Contingencies [Line Items]
Percentage of royalty payable on any revenue or other consideration receives from sub-licensees					20.00%		20.00%
Aggregate milestone payments made on obtaining regulatory approval									800,000
Aggregate payment to be made on attaining sales target					1,800,000		1,800,000
Aggregate payments made on achievement of milestones							2,500,000
Chief Scientist Of The State Of Israel [Member]
Commitments And Contingencies [Line Items]
Financial grants in support of research and development							2,000,000
Israel-United States Bi-National Industrial Research And Development [Member]
Commitments And Contingencies [Line Items]
Financial grants in support of research and development							$ 600,000